SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The Sales for the quarter ended June 2025 of Rs. 54.81 million declined by -57.48% from Rs. 128.89 millions.The Net Loss for the quarter ended June 2025 is Rs. -53.24 millions as compared to Net Loss of Rs. -51.71 millions of corresponding quarter ended June 2024 Operating profit Margin for the quarter ended June 2025 further decreased to -20.75% as compared to -21.63% of corresponding quarter ended June 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 54.81 128.89 -57.48 54.81 128.89 -57.48 433.12 504.22 -14.10
Other Income 0.12 0.34 -64.71 0.12 0.34 -64.71 7.09 4.51 57.21
PBIDT -20.75 -21.63 -4.07 -20.75 -21.63 -4.07 -143.21 -82.72 73.13
Interest 16.50 13.18 25.19 16.50 13.18 25.19 59.14 46.89 26.12
PBDT -37.25 -34.81 7.01 -37.25 -34.81 7.01 -202.35 -129.61 56.12
Depreciation 15.99 16.90 -5.38 15.99 16.90 -5.38 66.89 67.66 -1.14
PBT -53.24 -51.71 2.96 -53.24 -51.71 2.96 -269.24 -197.27 36.48
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.15 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -53.24 -51.71 2.96 -53.24 -51.71 2.96 -269.39 -197.27 36.56
Equity 215.61 215.61 0.00 215.61 215.61 0.00 215.61 215.61 0.00
PBIDTM(%) -37.86 -16.78 125.59 -37.86 -16.78 125.59 -33.06 -16.41 101.55

Krebs Biochem.&Inds Share Price

60.00 -2.15 (-3.46%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×